| Recruiting | PIC1 Injection Therapy for Relapsed/Refractory B-NHL Non-Hodgkin Lymphoma | Phase 1 | 2026-03-01 |
| Recruiting | Study of CD19 CAR-T Therapy for Refractory SLE Systemic Lupus Erythematosus | Phase 1 | 2026-02-01 |
| Recruiting | Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE Systemic Lupus Erythematosus | Phase 1 | 2026-01-26 |
| Recruiting | Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE Systemic Lupus Erythematosus | Phase 1 | 2026-01-01 |
| Recruiting | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors Renal Cell Carcinoma (RCC), Lung Cancer, Anaplastic Thyroid Carcinomas | Phase 1 | 2025-09-12 |
| Recruiting | CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors Lung Cancer, Gastric Cancer, Colon Cancer | Phase 1 | 2025-09-12 |
| Recruiting | Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc) | Phase 1 | 2025-09-01 |
| Recruiting | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma | Phase 1 | 2025-07-01 |
| Recruiting | Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE Systemic Lupus Erythematosus (SLE), Refractory | Phase 1 | 2025-06-12 |
| Recruiting | Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer Advanced Lung Cancer | Phase 1 | 2025-05-08 |
| Recruiting | Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Posi Advanced Lung Cancer | Phase 1 | 2025-04-28 |
| Recruiting | Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies T-ALL/Lymphoma | Phase 1 | 2025-03-27 |
| Recruiting | Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma Advanced Lung Cancer | Phase 1 | 2025-03-24 |
| Recruiting | A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer Advanced Lung Cancer | Phase 1 | 2024-12-12 |
| Recruiting | Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN AML (Acute Myeloid Leukemia), BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm) | Phase 1 | 2024-11-13 |
| Recruiting | Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment o Dermatomyositis, Juvenile, Dermatomyositis | Phase 1 | 2024-11-11 |
| Not Yet Recruiting | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | Phase 1 | 2024-11-01 |
| Recruiting | Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis Juvenile Dermatomyositis | Phase 1 | 2024-07-02 |
| Recruiting | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologi Ovarian Cancer, Cervix Cancer, Metastatic Cancer | Phase 1 | 2024-01-10 |
| Recruiting | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma B Cell Lymphoma, Non Hodgkin Lymphoma | Phase 1 | 2023-12-31 |
| Recruiting | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumo Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer | Phase 1 | 2023-11-30 |
| Recruiting | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malig Gastric Cancer, Colon Cancer, Rectal Cancer | Phase 1 | 2023-11-06 |
| Recruiting | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Gastric Cancer, Colon Cancer, Pancreas Cancer | Phase 1 | 2023-09-30 |
| Recruiting | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Gastric Cancer, Colon Cancer, Rectal Cancer | Phase 1 / Phase 2 | 2023-09-07 |
| Recruiting | Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmac Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Relapse Leukemia | Phase 1 / Phase 2 | 2023-08-31 |
| Recruiting | Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma | Phase 1 | 2023-08-31 |
| Recruiting | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid T Colorectal Cancer, Esophagus Cancer, Gastric Cancer | Phase 1 | 2023-08-11 |
| Unknown | A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma | Phase 1 | 2022-07-17 |
| Unknown | Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors Gastric Cancer, Colon Cancer, Rectal Cancer | Phase 1 / Phase 2 | 2022-06-07 |
| Recruiting | A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia | Phase 2 | 2022-01-26 |
| Unknown | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma | Phase 1 | 2021-12-31 |
| Unknown | Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer Metastatic Tumor, Renal Cell Carcinoma, Advanced Cancer | Phase 1 | 2021-12-31 |
| Unknown | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors Colorectal Cancer, Esophageal Cancer, Stomach Cancer | Phase 1 | 2021-09-10 |
| Unknown | Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non- Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma | Phase 1 | 2021-09-06 |
| Unknown | Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 1 | 2021-06-16 |
| Unknown | a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma B Cell Lymphoma | Phase 1 / Phase 2 | 2021-05-23 |
| Recruiting | a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plas Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse | Phase 1 / Phase 2 | 2021-03-07 |
| Recruiting | a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL B-ALL | Phase 1 / Phase 2 | 2021-03-07 |
| Unknown | Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | Phase 1 | 2020-10-26 |
| Unknown | Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lympho Leukemia, B-cell, Lymphoma, B-Cell | Phase 1 / Phase 2 | 2020-08-25 |
| Unknown | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer Solid Tumor, Lung Cancer, Colorectal Cancer | Phase 1 / Phase 2 | 2020-02-20 |
| Unknown | Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | 2019-12-01 |
| Unknown | Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasm, Plasma Cell | Phase 1 / Phase 2 | 2019-12-01 |
| Unknown | Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma Leukemia, Lymphoma, Leukemia, B-Cell | Phase 1 / Phase 2 | 2019-12-01 |
| Completed | Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolesce Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia | Phase 1 | 2019-11-05 |
| Unknown | CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | 2019-09-01 |
| Unknown | CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma Leukemia, B-cell, Lymphoma, B-Cell | Phase 1 / Phase 2 | 2019-09-01 |
| Unknown | CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma Leukemia, Lymphoma, Large B-Cell, Diffuse, Leukemia, B-cell | Phase 1 / Phase 2 | 2019-06-01 |
| Recruiting | BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse | Phase 1 / Phase 2 | 2019-04-01 |